Formulation and Packaging
Tablets of 400 mg + 25 mg.
Active ingredients: piracetam 400 mg and cinnarizine 25 mg. Inactive ingredients: lactose monohydrate 23.5 mg, magnesium hydroxycarbonate pentahydrate 46.8 mg, povidone K 30 3.9 mg, fumed silica 5.2 mg, calcium stearate monohydrate 5.2 mg and crospovidone 10.4 mg.
Application and Dosage
To be administered orally before or with meal. Dosage and length of treatment course shall be prescribed by a doctor. Dosage for adults is 1-2 tablets 3 times a day for 1-3 months depending on the severity of disease. Dosage for children is 1-2 tablets 1-2 times a day. Recommended length of treatment course is not more than 3 months.
Dyspepsia, headache, sleep disorders and allergic response.
- severe liver diseases;
- severe kidney diseases;
- children under 5 years of age;
- hypersensitivity to the components of the drug.
No cases of overdose were registered.
Omaron may enhance the sedative effect of CSN depressants, and the effect of nootropic drugs, antihypertensives and ethanol.
Its own effect is enhanced by vasodilating medicines.
When co-administered, Omaron improves of antipsychotic drugs and tricyclic antidepressants.
Storage Conditions and Shelf Life
Keep out of the reach of children. Store in a dark place at a temperature not higher than 25°C. Shelf life is 2 years.
Omaron is a combination drug which stimulates blood flow and neuronal metabolic processes in the brain and has antihypoxic, nootropic and vasodilating effects.
Its active ingredients are piracetam and cinnarizine. Piracetam stimulates metabolic processes in the brain by enhancing energy and protein metabolism, accelerating glucose processing in cells and increasing their resistance to hypoxia. It also improves synaptic transmission in the CNS and stimulates regional blood flow in the ischemic zone.
Cinnarizine is a beta blocker of slow calcium channels which prevents the entry of calcium ions into cells and reduces their content in the plasma membrane. It also reduces the tone of arteriole smooth muscles and their response to biogenic vasoconstrictors such as epinephrine, norepinephrine, dopamine, angiotensin and vasopressin. It has vasodilating effect (especially on blood vessels in the brain) as it enhances antihypoxic effect of piracetam without significantly affecting arterial pressure. Moreover, cinnarizine reduces the excitability of the vestibular apparatus and lowers the tone of the sympathetic nervous system showing antihistamine properties. It also increases the elasticity of erythrocyte membranes and improves blood viscosity.
- insufficient blood flow to the brain (including cerebral atherosclerosis and recovery from ischemic and hemorrhagic strokes and traumatic brain injuries);
- various types of encephalopathy;
- CNS diseases followed by reduced intellectual-mnestic functions such as memory, attention and mood disorders;
- psychoorganic syndrome with asthenia and adynamia;
- Ménière's disease;
- cognitive developmental delay in children;
- prevention of migraine and kinetosis.
- Lobzin et al (2009) Omaron in the treatment of vertebrobasilar insufficiency https://www.ncbi.nlm.nih.gov/pubmed/19156085
- Parfenov et al (2009) Use of omaron in patients with post-stroke cognitive disorders https://www.ncbi.nlm.nih.gov/pubmed/19672226
- I Stroganova, M Kiparisov (2010) Omaron in the restorative treatment of patients with chronic cerebrovascular insufficiency https://www.ncbi.nlm.nih.gov/pubmed/20443242
- Popova et al (2010) Omaron in the complex treatment of patients with multiple sclerosis https://www.ncbi.nlm.nih.gov/pubmed/21183917
- S Chuprina (2010) Omaron in the rehabilitation of post stroke outpatients https://www.ncbi.nlm.nih.gov/pubmed/20559275